13F filer · CIK 1281446
GREAT POINT PARTNERS LLC
Greenwich, CT · filing since Q3 2013 · last filing Aug 14, 2026
Reported value
$529.1M
+$94.0M vs prior
Positions
42
New / sold out
13 / 13
Added / reduced
7 / 9
Turnover
36.8%
buys $220.5M · sells $177.6M
Top-10 weight
51.6%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | ABIVAX SACALL | +400,000 | – | +$53.3M |
| New | ABIVAX SA | +204,314 | – | +$27.2M |
| New | ULTRAGENYX PHARMACEUTICAL INPUT | +600,000 | – | +$20.0M |
| New | DEFINIUM THERAPEUTICS INC | +425,000 | – | +$20.0M |
| Added | VERA THERAPEUTICS INC | +401,488 | +201.4% | +$17.2M |
| New | SAGIMET BIOSCIENCES INC | +2,029,933 | – | +$15.7M |
| Added | IMMIX BIOPHARMA INC | +927,642 | +265.0% | +$9.6M |
| Added | MOONLAKE IMMUNOTHERAPEUTICS | +355,813 | +71.2% | +$6.9M |
| New | INFLARX NV | +3,046,557 | – | +$6.8M |
| Added | OPUS GENETICS INC | +1,645,847 | +507.4% | +$6.8M |
10 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | APOGEE THERAPEUTICS INC | -374,000 | -100.0% | $-31.5M |
| Reduced | AMYLYX PHARMACEUTICALS INC | -1,050,000 | -60.0% | $-18.9M |
| Sold out | KALVISTA PHARMACEUTICALS INC | -675,000 | -100.0% | $-13.6M |
| Sold out | IMMUNOVANT INC | -545,625 | -100.0% | $-13.6M |
| Sold out | JADE BIOSCIENCES INC | -964,462 | -100.0% | $-13.6M |
| Sold out | ZENAS BIOPHARMA INC | -524,066 | -100.0% | $-10.2M |
| Reduced | NEKTAR THERAPEUTICS | -141,453 | -44.7% | $-9.9M |
| Reduced | BRIGHT MINDS BIOSCIENCES INC | -110,397 | -50.2% | $-7.7M |
| Sold out | COMPASS THERAPEUTICS INC | -1,350,000 | -100.0% | $-7.1M |
| Sold out | SCYNEXIS INC | -7,554,347 | -100.0% | $-6.9M |
12 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ABIVAX SACALLSPONSORED ADS | 400,000 | $53.3M | 10.07% |
| 2 | VOR BIOPHARMA INCCOM NEW | 1,700,000 | $31.3M | 5.91% |
| 3 | ABIVAX SASPONSORED ADS | 204,314 | $27.2M | 5.15% |
| 4 | IMMUNITYBIO INCPUTCOM | 3,000,800 | $26.3M | 4.97% |
| 5 | VERA THERAPEUTICS INCCL A | 600,836 | $25.8M | 4.87% |
| 6 | ZURA BIO LTDCLASS A ORD SHS | 4,215,930 | $24.9M | 4.70% |
| 7 | ALUMIS INCCOM | 856,061 | $24.1M | 4.55% |
| 8 | SOL-GEL TECHNOLOGIES LTDSHS NEW | 274,363 | $20.3M | 3.84% |
| 9 | ULTRAGENYX PHARMACEUTICAL INPUTCOM | 600,000 | $20.0M | 3.79% |
| 10 | DEFINIUM THERAPEUTICS INCCOM SHS | 425,000 | $20.0M | 3.78% |
32 more rows. Subscribe for $29/month to see every row, download the data and use the API.